arrow
B

Bing Xu

harbin medical university
H指数:38
被引数:5,004

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world treatment patterns and outcomes of brentuximab vedotin–based therapy in CD30-positive lymphomas in China: the prospective BRAVE study

中国CD30阳性淋巴瘤中基于 Brentuximab vedotin 的治疗模式与疗效:前瞻性 BRAVE 研究

2026-09-300
OA
Estimation of ED50 and ED95 of Oliceridine Required to Suppress the Bronchoscopy Response in Patients Undergoing Fiberoptic Bronchoscopy Under Sedation with Cipepofol: An Up-and-Down Sequential Allocation Trial

在Cipepofol镇静下进行纤维支气管镜检查时,抑制患者支气管镜反应所需Oliceridine的ED<sub>50</sub>和ED<sub>95</sub>的估计:一项上下序贯分配试验

2025-09-300
OAAI
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma

预后基因表达和微RNA表达谱特征以及原发性睾丸弥漫性大B细胞淋巴瘤的遗传改变

2025-07-170
PREAI
Arctigenin inhibits high glucose-induced EMT and cell proliferation to alleviate benign prostatic hyperplasia companied with type 2 diabetes mellitus through MBOAT4/ acylated Ghrelin/GHS-R

阿特吉根素通过MBOAT4/酰化生长素释放肽/GHS-R途径抑制高葡萄糖诱导的上皮-间质转化和细胞增殖,以缓解伴有2型糖尿病的良性前列腺增生。

2025-06-180
PRE
Extranodal diffuse large B-cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study

结外弥漫性大B细胞淋巴瘤:来自多中心EXPECT研究的临床与分子洞察及生存结局

2025-05-080
OAAI